PHC Holdings, a global healthcare company, led a CHF23m Series C round in Lunaphore Technologies, a Swiss life-sciences company developing innovative nextgeneration equipment for cancer research and tissue diagnostics. Existing investors including Redalpine Venture Partners, OCCIDENT and Alpana Ventures also participated in this financing round. "We are thrilled by the confidence placed in Lunaphore by our existing investors as well as the new ones in this financing round. The interest of global players in healthcare, like PHCHD demonstrates the relevance and added value of Lunaphore’s technology and confirms its high potential to transform the field of tissue analytics," Ata Tuna Ciftlik, Lunaphore CEO.